皇家华人

header-logo
GettyImages-609179959-hero
headshot

Binod Dhakal, MD

Associate Professor

view physician profile

Locations

  • Froedtert Hospital
  • Cancer Center - Froedtert Hospital

Specialties

  • Hematology
  • Medical Oncology

Languages

  • English, Nepali, Hindi

Cancer Center - Froedtert Hospital

Education

  • MD - Doctor of Medicine

Biography

Binod Dhakal, MD, MS, is Assistant Professor of Medicine, at the 皇家华人, Division of Hematology, specializing in multiple myeloma and plasma cell disorders. He graduated from Manipal College of Medical Sciences, Pokhara Nepal in 2004, completed Internal Medicine Residency at Saint Francis Hospital Evanston Illinois, and a fellowship in hematology/oncology at the 皇家华人, where he also served as a Chief Fellow. Prior to joining the fellowship, he was Assistant Professor of Medicine at the Medical College in Wisconsin in the Division of General Internal Medicine. He has authored numerous publications, including journal articles, meeting abstracts and book chapters. He has also won several awards during his fellowship which include the American Society of Clinical Oncology (ASCO) Merit Award; 皇家华人 Affiliated Hospitals (MCWAH) research award; Central Society for Clinical and Translational Research (CSCTR) best oral abstract and travel trainee award; American Society for Blood and Marrow Transplantation (ASBMT) clinical research training course; and, Outstanding Medical School Teacher award. Additionally, he was the recipient of the Mazie Froedtert Willms and Sue Froedtert Cancer Scholarship, and obtained his Master’s Degree in Clinical and Translational Science.

Research Interests

Dr. Dhakal's current research interests focus on novel drug treatments for patients with multiple myeloma and related plasma cell disorders by designing and conducting early phase clinical trials.

Publications

  • (Yohay S, Oloyede T, Kim S, Fang X, Dhakal B, Aijaz A, Mohan M, Narra R, Pasquini M, D'Souza A, Hamadani M, Freeman CL, Akhtar OS.) Br J Haematol. 2024 Dec;205(6):2370-2375 PMID: 39396814 SCOPUS ID: 2-s2.0-85206072300 10/14/2024

  • (Akhtar OS, Arshad S, Lian Q, Ahn KW, D'Souza A, Dhakal B, Mohan M, Pasquini M, Longo W, Shah NN, Fenske TS, Hamadani M.) Transplant Cell Ther. 2024 Dec;30(12):1191.e1-1191.e8 PMID: 39303985 SCOPUS ID: 2-s2.0-85206435293 09/21/2024

  • (Wu JF, Estrada-Merly N, Dhakal B, Mohan M, Narra RK, Pasquini MC, D'Souza A.) Transplant Cell Ther. 2024 Dec;30(12):1189.e1-1189.e10 PMID: 39277111 SCOPUS ID: 2-s2.0-85205846893 09/15/2024

  • (Yong K, Einsele H, Schecter JM, Roccia T, Deraedt W, Lendvai N, Slaughter A, Lonardi C, Connors K, Qi K, Londhe A, Carson R, Kharat A, Cost P, Valluri S, Mendes J, Pacaud L, Patel N, Florendo E, Dhakal B.) Eur J Cancer. 2024 Nov 29;215:115157 PMID: 39673835 12/15/2024

  • (Akhtar OS, Szabo A, Bhatlapenumarthi V, Forsberg M, Balev M, Patwari A, Cheruvalath H, Bhutani D, Thanendrarajan S, Dhakal B, Zangari M, Patel T, Shrestha A, Al-Hadidi S, Cooper D, Lentzsch S, van Rhee F, Shah MR, Bag A, D'Souza A, Schinke C, Chakraborty R, Shah N, Mohan M.) Br J Haematol. 2024 Nov;205(5):1830-1834 PMID: 39192546 SCOPUS ID: 2-s2.0-85202177578 08/28/2024

  • (Kim M, Arabi J, McCoy C, D'Souza A, Chhabra S, Abid MB, Thapa B, Dhakal B.) Clin Lymphoma Myeloma Leuk. 2024 Nov;24(11):804-807 PMID: 39043500 SCOPUS ID: 2-s2.0-85200365330 07/24/2024

  • (Dhakal B, Einsele H, Schecter JM, Deraedt W, Lendvai N, Slaughter A, Lonardi C, Nair S, He J, Kharat A, Cost P, Valluri S, Yong K.) Blood Adv. 2024 Oct 08;8(19):5062-5071 PMID: 39110988 PMCID: PMC11459902 SCOPUS ID: 2-s2.0-85206247561 08/07/2024

  • (Sidana S, Patel KK, Peres LC, Bansal R, Kocoglu MH, Shune L, Atrash S, Smith K, Midha S, Ferreri CJ, Dhakal B, Dima D, Costello P, Wagner C, Reshef R, Hosoya H, Mikkilineni L, Atanackovic D, Chhabra S, Parrondo RD, Nadeem O, Mann H, Kalariya N, Hovanky V, DeAvila G, Freeman CL, Locke FL, Alsina M, Wong S, Herr MM, Htut M, McGuirk JP, Sborov DW, Khouri J, Martin T, Janakiram M, Lin Y, Hansen DK.) Blood. 2024 Oct 04 PMID: 39365257 SCOPUS ID: 2-s2.0-85209775564 10/04/2024

  • (Chung DJ, Shah N, Wu J, Logan B, Bisharat L, Callander N, Cheloni G, Anderson K, Chodon T, Dhakal B, Devine S, Dutt PS, Efebera Y, Geller N, Ghiasuddin H, Hematti P, Holmberg L, Howard A, Johnson B, Karagkouni D, Lazarus HM, Malek E, McCarthy P, McKenna D, Mendizabal A, Nooka A, Munshi N, O'Donnell L, Patel K, Rapoport AP, Reese J, Rosenblatt J, Soiffer R, Stroopinsky D, Uhl L, Vlachos IS, Waller EK, Young JW, Pasquini MC, Avigan D.) Clin Cancer Res. 2024 Oct 01;30(19):4542 PMID: 39350638 PMCID: PMC11443237 SCOPUS ID: 2-s2.0-85205446162 10/01/2024

  • (Schinke C, Dhakal B, Mazzoni S, Shenoy S, Scott SA, Richards T, Le HH, DeBrosse A, Okorozo P, McDowell R, Patel S, Bunn J, Hawks K, Zhang X, Rodriguez C.) Curr Med Res Opin. 2024 Oct;40(10):1705-1711 PMID: 39177290 SCOPUS ID: 2-s2.0-85201809794 08/23/2024

  • (Chakraborty R, Cheruvalath H, Patwari A, Szabo A, Schinke C, Dhakal B, Lentzsch S, D'Souza A, Mohyuddin GR, Julian K, Midha S, Costello P, Kaiser M, Hing MNL, Harrison SJ, Cliff ERS, Mohan M.) Blood Cancer J. 2024 Aug 12;14(1):137 PMID: 39134535 PMCID: PMC11319778 SCOPUS ID: 2-s2.0-85201250452 08/13/2024

  • (San-Miguel J, Dhakal B, Patel N, Schecter JM, Lendvai N, Einsele H.) Future Oncol. 2024;20(33):2509-2520 PMID: 39110421 PMCID: PMC11537292 SCOPUS ID: 2-s2.0-85200761365 08/07/2024

Publications of from the

© 2024 皇家华人.  All rights reserved.  | Terms and Privacy 

Non-Discrimination Statement
The 皇家华人 (MCW) is committed to fostering a diverse community of outstanding faculty, staff, and students, as well as ensuring equal educational opportunity, employment, and access to services, programs, and activities, without regard to an individual's race, color, national origin, religion, age, disability, sex, gender identity/expression, sexual orientation, marital status, pregnancy, predisposing genetic characteristic, or military status. Employees, students, applicants or other members of the MCW community (including but not limited to vendors, visitors, and guests) may not be subjected to harassment that is prohibited by law or treated adversely or retaliated against based upon a protected characteristic. MCW’s policy as well as federal and state laws and regulations prohibit unlawful discrimination and harassment.